This study found that MS-275, a novel synthetic benzamide histone deacetylase inhibitor (HDACI), blocked Akt/mammalian target of rapamycin (mTOR) signaling in acute myelogenous leukemia (AML) HL60 and acute promyelocytic leukemia (APL) NB4 cells, as assessed by decreased levels of the phosphorylated (p)-Akt, p-p70 ribosomal S6 kinase (p70S6K) and p-S6K by western blot analysis. Interestingly, further inactivation of mTOR by rapamycin analog RAD001 (everolimus) significantly enhanced MS-275-mediated growth inhibition and apoptosis of these cells in parallel with enhanced upregulation of p27 kip1 and downregulation of c-Myc. In addition, RAD001 potentiated the ability of MS-275 to induce differentiation of HL60 and NB4 cells, as measured by the expression of CD11b cell surface antigens, as well as reduction of nitroblue tetrazolium. Importantly, RAD001 potentiated the ability of MS-275 to induce the expression of the myeloid differentiation-related transcription factor, CCAAT enhancer-binding protein-e, in these cells in association with enhanced acetylation of histone H3 on its promoter. Furthermore, RAD001 (5 mg/kg) significantly enhanced the effects of MS-275 (10 mg/kg) to inhibit proliferation of HL60 tumor xenografts in nude mice without adverse effects. Taken together, concomitant administration of an HDACI and an mTOR inhibitor may be a promising treatment strategy for the individuals with a subset of human leukemia.
Introduction
Acute myelogenous leukemia (AML) is a lethal disease, resulting from the clonal expansion and accumulation of hematopoietic stem cells arrested at various stages of development. 1 Intensification of chemotherapy has led to remissions in 70-85% of individuals with AML, and postremission relapses occur frequently. 2, 3 Recent studies found that the genotype of mutant nucleophosmin (NPM1) without FLT3 internal tandem duplications and the mutant CCAAT/enhancer-binding protein-a (CEBPA) were significantly associated with complete remission in individuals with cytogenetically normal AML. 4 In addition, these studies found that individuals with wild-type NPM1 benefited from hematopoietic stem cell transplantation from an HLA-matched related donor; 4 however, regimen-related toxicities and relapse remain serious problems. 5 Histone deacetylase inhibitors (HDACIs) have emerged as a potentially promising new class of anticancer drugs. 6 These include the hydroxamic acid-derived suberoylanilide hydroxamic acid (SAHA, Vorinostat), LBH 589, tricostatin A, cyclic depsipeptide FR901228, valproic acid and the benzamide MS-275. 7 HDACIs induce growth arrest and apoptosis of cancer cells by manipulating the transcription of genes involved in the regulation of the cell cycle and apoptosis, as well as differentiation. 6 For example, we previously showed that SAHA and MS-275 induced growth arrest and apoptosis of human mantle cell lymphoma and adult T-cell leukemia cells, respectively, in association with the induction of histone acetylation of the p21 waf1 promoter region, resulting in the upregulation of p21 waf1 protein. 7, 8 Promyelocytic leukemia/retinoic acid (RA) receptor-a fusion protein, generated by chromosomal translocation in acute promyelocytic leukemia (APL) recruits HDAC and repressor complexes on RA target promoters and silences RA signaling, resulting in the differentiation block of hematopoietic stem cells. 9 RA, at pharmacological concentration, dissociates HDAC and repressor complexes and recruits coactivators to the promoter and activates RA signaling, resulting in terminal differentiation. 9 HDACI modifies chromatin structure and increases promoter accessibility, leading to transcriptional activation. 10 HDACI increased sensitivity of APL cells to RA-induced differentiation. 11 Valproic acid, the antiepileptic drug, induced differentiation and apoptosis of AML cells in a murine model through the inhibition of HDAC. 12 The clinical efficacy of valproic acid as monotherapy or in combination with all-trans-RA has recently been shown in individuals with AML and myelodysplastic syndromes. 13 The CCAAT enhancer-binding protein-e (C/EBPe) is a family of transcription factors that regulates proliferation and differentiation of numerous cell types including granulocytes. 14, 15 We and others previously showed that C/EBPe is pivotal to granulocytic differentiation. 16, 17 C/EBPe modulates the levels of various cellcycle regulating molecules during differentiation; overexpression of C/EBPe downregulated the levels of c-Myc and upregulated the levels of cyclin-dependent kinase inhibitor p27 kip1 in myeloid cells. 18, 19 The serine/threonine kinase mammalian target of rapamycin (mTOR) is activated by PI3K/Akt signaling and regulates cell proliferation in part by ribosomal protein translation and the initiation of cap-dependent translation. 20, 21 mTOR phosphorylates p70 ribosomal S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP-1), and increases the translation of mRNAs with long, highly structured 5 0 -untranslated regions, such as cyclin D1 and c-Myc, which regulate cell-cycle transition from G1 to S phase. 20, 21 The mTOR inhibitors, rapamycin or its analog RAD001 (everolimus) have been shown to be active against many types of solid tumors as well as subsets of leukemia, and are now being under evaluation in clinical trials. 22 This study found that MS-275 induced growth arrest, apoptosis, and differentiation of AML cells in association with the blockade of mTOR signaling. Further inhibition of mTOR signaling by RAD001 significantly potentiated the ability of MS-275 in AML cells in vitro and in vivo. Notably, RAD001 augmented MS-275-mediated acetylation of histone H3 on C/EBPe promoter, resulting in enhanced upregulation of C/EBPe in AML cells. Moreover, RAD001 significantly enhanced MS-275-inducded growth inhibition of HL60 tumor xenografts in nude mice without adverse effects.
Materials and methods

Reagents
MS-275 and RAD001 were provided by Schering AG (Berlin, Germany) and Novartis (Basel, Switzerland), respectively. These reagents were dissolved in 100% dimethyl sulfoxide to a stock concentration of 10 À2 M and stored at À80 1C. For animal studies, RAD001 and MS-275 were diluted in double-distilled water just before administration by gavage.
Cells
HL60 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). NB4 cell line was a kind gift from M Lanotte (St Louis Hospital, Paris, France). Cells were grown in RPMI 1640 containing 10% fetal bovine serum.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays Cells (5 Â 10 5 /ml) were cultured with various concentrations of MS-275 (0.1-1 mM) and/or RAD001 (3-100 nM) for 2 days in 96-well plates. MTT assay was performed as described previously. 23 All experiments were performed in triplicate and repeated at least three times.
Cell-cycle analysis by flow cytometry
Cell cycle analysis was performed on HL60 and NB4 cells incubated with various concentrations of either MS-275 and/or RAD001, as previously described. 24 
Apoptosis assays
The ability of MS-275 and/or RAD001 to induce apoptosis in leukemia cells was measured using the annexin V-FITC apoptosis detection kit (Pharmingen Inc., San Diego, CA, USA), as described previously. 25 
Assays for differentiation of leukemia cells
The HL60 and NB4 cells (5 Â 10 5 /ml) were seeded in 12-well plates and were cultured with various concentrations of either MS-275 and/or RAD001. After 2 days, expression of CD11b on their cell surface was measured by staining with a Fluorescein (FITC)-conjugated anti-CD11b mAb (Dako, Glostrup, Denmark) using flow cytometry. For NBT measurements, cells (5 Â 10 5 /ml) were incubated in 12-well plates (Corning, Corning, NY, USA) for 2 days as described above. After incubation, each cell suspension was mixed with an equal volume of RPMI 1640 containing 1 mg/ml NBT (Sigma, St Louis, MO, USA) and 10 À6 mol/l 12-0-tetradecanoyl-13-acetate (TPA; Sigma) for 20 min at 37 1C. The cells were washed in phosphate-buffered saline, cytocentrifuged, fixed in methanol for 5 min, and stained with Gram safranin for 10 min at room temperature; 300 cells were analyzed for blue dye using light microscopy, as described previously. 26 
Western blot analysis
Western blot analysis was performed as described previously. 27 The membrane was probed sequentially with the antibodies. 
Chromatin immunoprecipitation assay
NB4 and HL60 cells (1 Â 10 6 /ml) were cultured with MS-275 (0.3 mM) and/or RAD001 (10 nM) for 2 days. Untreated cells were used as controls. Formaldehyde was added to the cells to a final concentration of 1%, and the cells were incubated at 37 1C for 10 min. The cells were collected and subjected to chromatin immunoprecipitation utilizing reagents provided by LPBIO (Lake Placid, NY, USA), as described previously. 28 Antiacetylated histone H3 antibody (Upstate, Lake Placid, NY, USA) was used for immunoprecipitation. Immunoprecipitated DNA was recovered and used as a template for real-time PCR. The primers for C/EBPe promoter were as follows: forward, 5
0 -GGAAAAGGAAG-CAGAGCAGA-3 0 reverse, 5 0 -TCGATCTTCTGCCCTAGACC-3 0 . Real-time PCR was carried out by using Power SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK), as described previously. 29 The amplified sequences were normalized to those form cross-linked DNA/protein complexes which were not immunoprecipitated with antiacetylated histone H3 antibody, as described previously. 30 
Mice
Female immune deficient BALB/c nude mice at 4 weeks of age were purchased from JAPAN SLC Inc. (Shizuoka, Japan), and were maintained in pathogen-free conditions with irradiated chow. Animals were bilaterally, s.c. injected with 2 Â 10 6 HL60 cells/ tumor in 0.1 ml Matrigel (Collaborative Biomedical Products, Bedford, MA, USA). When HL60 cells formed palpable tumors, mice were divided randomly into four groups receiving control (n ¼ 5), or either RAD001 (n ¼ 5) or MS-275 (n ¼ 5), or combination of both RAD001 and MS-275 (n ¼ 5). MS-275 (10 mg/kg) was given to mice orally six times during 2 weeks. RAD001 (5 mg/kg) was given to mice orally four times during a week. The dose of these agents was determined by our preliminary studies (data not shown). Control diluent was given to the untreated control mice. Body weight and tumors were measured twice a week. Tumor sizes were calculated by the formula: a Â b Â c, where 'a' is the length and 'b' is the width and 'c' is the height in millimeters. At the end of the experiment, animals were killed by CO 2 asphyxiation and tumor weights were measured after their careful resection. Tumor tissue was collected for analysis. The experiments were approved by the Review Board of Kochi University.
Statistical analysis
Statistical analysis was performed to assess the difference between two groups under multiple conditions by one-way analysis of variance followed by Boneferroni's multiple comparison tests using PRISM statistical analysis software (GraphPad Software Inc., San Diego, CA, USA).
Results
MS-275 inhibits Akt/mTOR signaling in AML cells
Exposure of HL60 and NB4 cells to MS-275 (0.1-1 mM, 48 h) inhibited their proliferation with the concentration that inhibits cell proliferation by 50% (IC50) values of approximately 0.8 and 0.9 mM, respectively as measured by MTT assay (figure not shown). Western blot analyses showed that both HL60 and NB4 cells constitutively expressed phosphorylated forms of Akt and mTOR substrates p70S6K and S6K (Figure 1) . Exposure of these cells to MS-275 (0.1-1 mM, 48 h) effectively downregulated the levels of the phosphorylated forms of Akt, p70S6K and S6K without modulating total amount of these proteins, suggesting that MS-275 inhibited the activation 
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Leukemia of the mTOR signal pathway (Figure 1 ). These cells also constitutively expressed phosphorylated forms of ERK, which was downregulated after exposure to MS-275 (0.1-1 mM, 48 h); however, effects of MS-275 (0.3 or 1 mM) on p-ERK appeared to be less potent compared to those on Akt signaling (Figure 1 ).
Blockade of mTOR signaling potentiates the ability of HDACI to inhibit proliferation of AML cells MS-275 blocked Akt/mTOR signaling in AML cells (Figure 1) . We, therefore, explored the drug interaction of MS-275 and RAD001, the inhibitor of mTOR in these cells. RAD001 (10 nM) significantly potentiated the ability of MS-275 (0.1-1 mM) to inhibit the proliferation of HL60 and NB4 cells as measured by MTT assay on the second day of culture (Figures 2a and b) .
Blockade of mTOR signaling potentiates the ability of MS-275 to induce apoptosis of leukemia cells
Cell-cycle analysis showed that exposure of HL60 and NB4 cells to MS-275 (1 mM, 48 h) induced the accumulation of cells in the pre-G1 phase of the cell cycle, a feature characteristic of apoptosis (Figures 2c and d) . RAD001 (10 nM, 48 h) alone did not induce the accumulation of cells in pre-G1 phase of cell cycle. However, when MS-275 was combined with RAD001, the proportion of cells in pre-G1 phase of the cell cycle dramatically increased compared to either alone (Po0.01); Figures 2c and d. For example, either MS-275 (1 mM, 48 h) or RAD001 (10 nM, 48 h) alone caused an accumulation of 52 ± 10% and 4 ± 2% (mean ± s.d.) of HL60 cells in the pre-G1 phase, respectively. When these cells were exposed simultaneously to both of these compounds at the same concentration, the proportion of cells in the pre-G1 phase of the cell cycle increased to a mean 87±3.8% (Figure 2c) .
The ability of RAD001 to enhance MS-275-induced apoptosis of leukemia cells was further confirmed by annexin V staining. Exposure of HL60 cells to MS-275 (1 mM, 48 h) alone resulted in 68±4% of HL60 cells becoming annexin V positive. On the other hand, exposure of HL60 cells to RAD001 (10 nM, 48 h) alone did not induce apoptosis of HL60 cells. When these cells were exposed to the combination of both at the same concentration, a mean 89±1% of cells became annexin V positive (Po0.01 with respect to either compound alone; Figure 2e) . Similarly, MS-275-induced apoptosis of NB4 cells was significantly potentiated in the presence of RAD001 (Figure 2f ).
RAD001 enhanced MS-275-induced differentiation of AML cells
We examined the ability of MS-275 to induce differentiation of AML cells by quantifying CD11b expressing population, a marker of myeloid differentiation, by flow cytometry. Exposure of HL60 or NB4 cells to MS-275 (0.1 or 0.3 mM) for 48 h induced expression of CD11b antigen on their cell surface in a dosedependent manner. Effect of RAD001 on the expression of CD11b was negligible; however, when MS-275 (0.1 or 0.3 mM) was combined with RAD001 (10 nM), proportion of cells expressing CD11b antigen was dramatically increased (Figures  3a and b) . The production of superoxide is a marker of granulocyte-like differentiation, which can be measured by the ability to reduce NBT. 25 Using this marker, we examined the ability of MS-275 and RAD001 in combination to induce differentiation of HL-60 and NB4 cells. 
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C Nishioka et al of HL-60 cells to reduce NBT, respectively. RAD001 (10 nM, 48 h) alone induced 7±1% of cells to reduce NBT. When both compounds were combined at the same concentration, a mean of 32 or 39% of HL-60 cells reduced NBT (Figure 3c) . Similarly, RAD001 (10 nM, 48 h) enhanced the ability of MS-275 (0.1 mM, 48 h) to reduce NBT in NB4 cells (Figure 3d ). However, when higher dose of MS-275 (0.3 mM) was combined with RAD001 (10 nM), proportion of cells with reduced NBT decreased (Figure 3d) , mainly because cells underwent apoptosis rather than differentiation (data not shown).
Effect of MS-275 and RAD001 on expression of proteins important in regulating cell cycle and differentiation in leukemia cells
We next examined whether MS-275 and RAD001 modulated levels of C/EBPe, c-Myc, and p27 kip1 in leukemia cells by western blot analysis (Figure 4 
kip1 When HL60 and NB4 cells were exposed to the combination of both at the same concentration, levels of these proteins were markedly upregulated (Figure 4a) . Effect of MS-275 (0.3 mM, 48 h) or RAD001 (10 nM, 48 h) on levels of c-Myc was negligible in NB4 and HL60 cells; however, combination of both compounds at the same concentration dramatically downregulated the levels of c-Myc in these cells (Figure 4a ). MS-275 in combination with RAD001 completely blocked the expression of p-S6K and p-p70S6K in these cells (Figure 4b) , suggesting that mTOR signaling was effectively blocked.
RAD001 enhanced MS-275-induced acetylation of histone H3 on the C/EBPe promoter in leukemia cells 1 mM) and/or RAD001 (10 nM). After 48 h, cells were harvested and subjected to chromatin immunoprecipitation followed by real-time PCR. The amplified sequences were normalized to those form input (the crosslinked DNA/protein complexes, which were not immunoprecipitated with antiacetylated histone H3 antibody). The statistical significance of difference between acetylation of histone H3 induced by either MS-275 and/or RAD001 was determined by ANOVA followed by Boneferroni's multiple comparison tests. Results represent the mean of four experiments performed in duplicate; *Po0.01, with respect to control.
slightly induced acetyl-histone H3 proteins in NB4 cells (Figure 5a ). Both of MS-275 and RAD001 slightly induced acetyl-histone H3 proteins in HL60 cells (Figure 5a ). When these cells were exposed to both agents at the same concentration, levels of acetyl-histone H3 dramatically increased (Figure 5a ).
We next examined the effect of MS-275 and RAD001 in combination on acetylation of histone H3 around the C/EBPe gene by chromatin immunoprecipitation assay. To quantify acetylated DNA precisely, we employed real-time PCR. As shown in Figure 5b , exposure of HL60 and NB4 cells to RAD001 (10 nM) and MS-275 (0.1 mM) in combination for 48 h prominently enhanced acetylation of histone H3 on the C/EBPe promoter in these two cell lines.
RAD001 enhanced the ability of MS-275 to inhibit the proliferation of human HL60 leukemic xenografts in vivo
We further evaluated the antiproliferative activity of MS-275 combined with RAD001 in vivo ( Figure 6 ). MS-275 (10 mg/kg) or RAD001 (5 mg/kg) alone inhibited the proliferation of HL60 xenografts by approximately 40 or 50%, respectively compared with control tumors (Figure 6a ). When mice were treated with both compounds, tumor growth was inhibited by nearly 75% (Figure 5a ), resulting in decreased weights of HL60 tumors at autopsy (Figure 6b) . None of the treated mice show signs of illness or significant weight loss (Figure 6c ).
Discussion
This study, for the first time, showed that the inhibition of mTOR dramatically potentiated the ability of HDACI to acetyl-histone H3 in leukemia cells ( Figure 5 ). RAD001 markedly increased MS-275-stimulated acetylation of histone H3 on C/EBPe promoter and enhanced its expression in HL60 and NB4 cells (Figures 4, 5 and 7) , which was associated with increased differentiation of these cells (Figure 3) . In parallel, MS-275 in combination with RAD001 upregulated levels of p27 kip1 and downregulated the levels of c-Myc proteins (Figures 4 and 7) .
MS-275-induced growth arrest, apoptosis and differentiation of AML cells appeared to be dose-dependent. Low dose of MS-275 (0.1 or 0.3 mM) induced differentiation of these cells in association with increased levels of C/EBPe (Figures 3 and 4) . When these cells were exposed to higher dose of MS-275 (1 mM), induction of apoptosis was prominent in parallel with blockade of Akt/mTOR signaling (Figures 1 and 2) . Similarly, previous studies showed that MS-275 exerted dose-dependent effects in human leukemia cells (U937, HL60, K562 and Jurkat); it induced growth arrest and differentiation of leukemia cells at low concentrations. On the other hand, higher dose of MS-275 caused marked apoptosis of leukemia cells. 31 These investigators showed that high dose of MS-275 generated reactive oxygen species in leukemia cells followed by the loss of mitochondrial membrane potential and cytosolic release of cytochrome C, resulting in the activation of caspase cascade and apoptosis. 31 Another study also found that MS-275 produced ROS and activated caspases, leading to apoptosis of chronic lymphocytic leukemia cells. 32 We have recently shown that MS-275 inhibited the nuclear factor kB, which stimulated a variety of antiapoptotic molecules, such as bcl-2 family members, and induced growth arrest and apoptosis of adult T-cell leukemia cells. 8 We have recently shown that SAHA (vorinostat), one of the HDACI derived from hydroxamic acid, also inhibited Akt/mTOR signaling, resulting in the downregulation of cyclin D1 in mantle cell lymphoma cells. 33 In addition, other investigators found that SAHA as well as tricostatin A inhibited Akt activity in prostate cancer cells. 34 These observations suggested that Akt signal pathway may be a common target of HDACI.
The Akt/mTOR signal pathway negatively regulates granulocytic differentiation; all-trans RA induced myeloid differentiation of APL cells in conjunction with inactivation of the Akt/ mTOR signal pathway. 35, 36 We have recently identified RTP801, the stress responsive gene, as one of the all-trans-RA -target genes responsive to all-trans-RA -mediated differentiation of AML cells. RTP801 is a negative regulator of the mTOR pathway. 37 It is unlikely that MS-275 induced differentiation of AML cells and inhibited mTOR signaling through RTP801. MS-275 inhibited both Akt and mTOR ( Figure 1) ; however, RTP801 was shown to inhibit mTOR but not Akt. 38 The MEK/ERK signal pathway is another prosurvival signal pathway activated in AML. We have recently shown that MS-275 also inhibited MEK/ERK signaling in AML cells. Interestingly, further inactivation of MEK/ERK signaling by AZD6244 enhanced MS-275-mediated acetylation of histone H3 on p21 waf1 promoter, resulting in marked upregulation of p21 waf1 protein and induction of apoptosis of AML cells. 28 Contrary to this study, inhibition of MEK/ERK signaling blunted MS-275-induced differentiation of AML cells. 28 Taken together, the combination of MS-275 and RAD001 may be useful for treatment of individuals with a subset of AML. Further studies are required to verify the molecular mechanisms by which blockade of mTOR signaling affects chromatin remodeling. 
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